MF6 Stock Overview
Develops advanced nanomedicine for cancer therapies. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
MagForce AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.001 |
52 Week High | €0.0098 |
52 Week Low | €0.0002 |
Beta | 0 |
11 Month Change | 0% |
3 Month Change | 100.00% |
1 Year Change | -37.50% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -84.38% |
Recent News & Updates
Recent updates
Shareholder Returns
MF6 | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | 0% | -1.0% | -0.02% |
1Y | -37.5% | -7.3% | 8.2% |
Return vs Industry: MF6 underperformed the German Medical Equipment industry which returned -7.3% over the past year.
Return vs Market: MF6 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
MF6 volatility | |
---|---|
MF6 Average Weekly Movement | 80.4% |
Medical Equipment Industry Average Movement | 5.4% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.9% |
10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: MF6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MF6's weekly volatility has decreased from 101% to 80% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | n/a | Ben Lipps | www.magforce.de/ |
MagForce AG develops advanced nanomedicine for cancer therapies. It offers NanoTherm therapy system, a combination of medical devices for the treatment of solid brain tumors; NanoPlan, a software that stimulates the temperature distribution in the treatment area; NanoTherm, a magnetic ferrofluid; and NanoActivator, a magnetic field generator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.
MagForce AG Fundamentals Summary
MF6 fundamental statistics | |
---|---|
Market cap | €30.57k |
Earnings (TTM) | -€10.57m |
Revenue (TTM) | €1.08m |
0.0x
P/S Ratio0.0x
P/E RatioIs MF6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MF6 income statement (TTM) | |
---|---|
Revenue | €1.08m |
Cost of Revenue | €918.75k |
Gross Profit | €158.39k |
Other Expenses | €10.73m |
Earnings | -€10.57m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did MF6 perform over the long term?
See historical performance and comparison